UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 43

Sortiert nach

Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist

Journal of clinical pharmacology, 2023-09, Vol.63 (9), p.1017-1025

2023

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers

Clinical and translational science, 2023-03, Vol.16 (3), p.536-547

2023

Volltextzugriff (PDF)

Effects of Tobacco Smoking and Nicotine on Cancer Treatment

Pharmacotherapy, 2012-10, Vol.32 (10), p.920-931

2012

Volltextzugriff (PDF)

Feasibility of Using Population Pharmacokinetics‐Based Virtual Control Groups in Organ Impairment Studies

Journal of clinical pharmacology, 2024-06, Vol.64 (6), p.713-718

2024

Volltextzugriff (PDF)

Characterization of the US Food and Drug Administration Post-Marketing Commitments and Requirements for Pregnancy and Lactation

Clinical pharmacology and therapeutics, 2023-12, Vol.114 (6), p.1238-1242

2023

Volltextzugriff (PDF)

Trends in FDA Transporter‐Based Post‐Marketing Requirements and Commitments Over the Last Decade

Clinical pharmacology and therapeutics, 2022-09, Vol.112 (3), p.635-642

2022

Volltextzugriff (PDF)

Overview of Clinical Pharmacology Packages of New Drug Applications Approved for the Treatment of Rare Diseases

Journal of clinical pharmacology, 2022-12, Vol.62 (S2), p.S72-S78

2022

Volltextzugriff (PDF)

Influence of pH on the dissolution of folic acid supplements

International journal of pharmaceutics, 2009-02, Vol.367 (1), p.97-102

2009

Volltextzugriff (PDF)

Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications

JAMA psychiatry (Chicago, Ill.), 2020-10, Vol.77 (10), p.1064

2020

Volltextzugriff (PDF)

Evaluation of US Food and Drug Administration Drug Label Recommendations for Coadministration of Antivirals and Acid‐Reducing Agents

Clinical pharmacology and therapeutics, 2022-11, Vol.112 (5), p.1088-1097

2022

Volltextzugriff (PDF)

Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl‐Coenzyme A Carboxylase Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist

Journal of clinical pharmacology, 2023-05, Vol.63 (5), p.560-568

2023

Volltextzugriff (PDF)

Methadone Metabolism and Drug-Drug Interactions: In Vitro and In Vivo Literature Review

Journal of pharmaceutical sciences, 2018-12, Vol.107 (12), p.2983-2991

2018

Volltextzugriff (PDF)

Model‐Informed Approaches and Innovative Clinical Trial Design for Adeno‐Associated Viral Vector‐Based Gene Therapy Product Development: A White Paper

Clinical pharmacology and therapeutics, 2023-09, Vol.114 (3), p.515-529

2023

Volltextzugriff (PDF)

Concordance of Exposure Changes Because of Renal Impairment Between Results of Dedicated Renal Impairment Studies and Population Pharmacokinetic Predictions

Journal of clinical pharmacology, 2021-10, Vol.61 (10), p.1324-1333

2021

Volltextzugriff (PDF)

New Horizons of Model Informed Drug Development in Rare Diseases Drug Development

Clinical pharmacology and therapeutics, 2024-07

2024

Volltextzugriff (PDF)

Pharmacokinetics and Safety of Firsocostat, an Acetyl‐Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment

Journal of clinical pharmacology, 2024-07, Vol.64 (7), p.878-886

2024

Volltextzugriff (PDF)

Drug‐Drug Interaction Studies of Methadone and Antiviral Drugs: Lessons Learned

Journal of clinical pharmacology, 2019-08, Vol.59 (8), p.1035-1043

2019

Volltextzugriff (PDF)

Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1

The Journal of pharmacology and experimental therapeutics, 2008-12, Vol.327 (3), p.770

2008

Volltextzugriff (PDF)

Stable Isotope Pharmacokinetic Studies Provide Insight into Effects of Age, Sex, and Weight on Levothyroxine Metabolism

Thyroid (New York, N.Y.), 2018-01, Vol.28 (1), p.41

2018

Volltextzugriff (PDF)

Evaluation of the Effects of Meal Type and Acid‐Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist

Clinical pharmacology in drug development, 2024-06, Vol.13 (6), p.677-687

2024

Volltextzugriff (PDF)

Dosing Recommendations for Quetiapine When Coadministered With HIV Protease Inhibitors

Journal of clinical pharmacology, 2019-04, Vol.59 (4), p.500-509

2019

Volltextzugriff (PDF)

Treatment and Prevention of CMV Disease in Transplant Recipients: Current Knowledge and Future Perspectives

Journal of clinical pharmacology, 2019-06, Vol.59 (6), p.784-798

2019

Volltextzugriff (PDF)

Design Features of Drug-Drug Interaction Trials Between Antivirals and Oral Contraceptives

Journal of clinical pharmacology, 2016-05, Vol.56 (5), p.541-547

2016

Volltextzugriff (PDF)

Utility of Model‐Based Approaches for Informing Dosing Recommendations in Specific Populations: Report From the Public AAPS Workshop

Journal of clinical pharmacology, 2017-01, Vol.57 (1), p.105-109

2017

Volltextzugriff (PDF)

An integrated clinical pharmacology approach for deriving dosing recommendations in a regulatory setting: Review of recent cases in psychiatry drugs

Journal of clinical pharmacology, 2013-10, Vol.53 (10), p.1005-1009

2013

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(42)
Tagungsberichte
(1)

Sprache

Englisch
(43)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist

Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers

Effects of Tobacco Smoking and Nicotine on Cancer Treatment

Feasibility of Using Population Pharmacokinetics‐Based Virtual Control Groups in Organ Impairment Studies

Characterization of the US Food and Drug Administration Post-Marketing Commitments and Requirements for Pregnancy and Lactation

Trends in FDA Transporter‐Based Post‐Marketing Requirements and Commitments Over the Last Decade

Overview of Clinical Pharmacology Packages of New Drug Applications Approved for the Treatment of Rare Diseases

Influence of pH on the dissolution of folic acid supplements

Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications

Evaluation of US Food and Drug Administration Drug Label Recommendations for Coadministration of Antivirals and Acid‐Reducing Agents

Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl‐Coenzyme A Carboxylase Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist

Methadone Metabolism and Drug-Drug Interactions: In Vitro and In Vivo Literature Review

Model‐Informed Approaches and Innovative Clinical Trial Design for Adeno‐Associated Viral Vector‐Based Gene Therapy Product Development: A White Paper

Concordance of Exposure Changes Because of Renal Impairment Between Results of Dedicated Renal Impairment Studies and Population Pharmacokinetic Predictions

New Horizons of Model Informed Drug Development in Rare Diseases Drug Development

Pharmacokinetics and Safety of Firsocostat, an Acetyl‐Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment

Drug‐Drug Interaction Studies of Methadone and Antiviral Drugs: Lessons Learned

Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1

Stable Isotope Pharmacokinetic Studies Provide Insight into Effects of Age, Sex, and Weight on Levothyroxine Metabolism

Evaluation of the Effects of Meal Type and Acid‐Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist

Dosing Recommendations for Quetiapine When Coadministered With HIV Protease Inhibitors

Treatment and Prevention of CMV Disease in Transplant Recipients: Current Knowledge and Future Perspectives

Design Features of Drug-Drug Interaction Trials Between Antivirals and Oral Contraceptives

Utility of Model‐Based Approaches for Informing Dosing Recommendations in Specific Populations: Report From the Public AAPS Workshop

An integrated clinical pharmacology approach for deriving dosing recommendations in a regulatory setting: Review of recent cases in psychiatry drugs

Suchergebnisse filtern